GSK (GSK) stock

Medicines and vaccines , market cap $101B

Medicines and vaccines

Worth $101B

Pre-market

$51.10

+1.53%

Close $50.33 -0.16%

As of 8:53 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Average

In its industry

#19of 90

Pharma

Checks firing

3of 14

Choppy

From 52-week high

-18.4%

under its best in a year

GSK's Quality Score was unchanged on Fri, Nov 6, at 10.

Follow GSK's trial news. Pro members can get an alert when GSK files news, and see its trials, share raises, and its CEO's filings.

Get an alert when GSK files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextMar 1, 2027 · In 112 daysDepemokimab, Phase 3 GLIDE, the sponsor's estimatePhase 3 main data due · ClinicalTrials.gov · Aug 26

Why is GSK down?

Down 1.2% on Oct 21 while the S&P 500 rose 0.5%.

Pharma stocks fell a median 0.5% that day (86 stocks); GSK fell 1.2%.

Sources: Price history, Oct 21, 2026

1 more reason, free with an account →The timeline and its peers, for Pro members.

Key facts on GSK

Key facts on GSK
The company	Profit up 113% to £6.3B
Latest filing	6-K, Oct 26 Issued a release: "Issued: 24 October 2026, London UK Jemperli (dostarlimab) data show 76% of patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response"

1 more reason behind GSK's 10, free with an account →2 more reasons behind GSK's 10, for Pro members.

GSK in the news

Wed Nov 4HP picks GSK restructuring veteran Walmsley as CEO, shares jump over 6% Reuters and 1 more GSK closed +5.0% that day.

Big story

Restructuring

GSK plans to cut up to 1,217 jobs in Belgium as it begins three-year restructuring plan

GSK closed +3.5% that day on 1.9x normal volume.

Reported by Reuters · covered by 6 outlets

Get an alert on GSK's next big story →

What's next

Mon Nov 9: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

5 more dates ahead: conferences and dividend dates, for Pro members.

GSK catalysts

Coming up

After its last 4 reports it closed +1.2% on average, higher 2 of 4 times.

35 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for GSK

Next Phase 3 data on the registry

Mar 1, 2027In 112 daysDepemokimab, Phase 3 GLIDE: A Study of Depemokimab in Participants of 6 to 11 Years of AgePhase 3 main data due · ClinicalTrials.gov · Aug 26

What it means: the date the registry lists for the trial’s last main measurement, as the sponsor estimates it. Results usually follow weeks to months later.

Lead program: Depemokimab
Another trial: Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgePhase 3 · Recruiting · 750 people · main data estimated Nov 23, 2026 · NCT06693895

168 more trials, 14 with data due this year, 23 drugs past Phase 1 and 725 filings, for Pro members.

Dilution on the horizon

Shelf registration (F-3ASR, filed Mar 25, 2024)

For Pro members: the amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when GSK files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why GSK scores 10

Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
+3News FDA approval, earnings beat, guidance cut

Long-term trend adds
Size adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.

No effect today: Run-up, Growth, Dilution, Volatility, Cash flow, and Persistence.

What every line is worth, and the reason behind it, on GSK and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:53 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when GSK's Quality Score turns up

A free account. No card.

How GSK ranks in Pharma

GSK is #19 of 90 by Quality Score.

How GSK ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	8/14	24
2	LLYEli Lilly	5/14	18
3	CRONCronos	5/14	18
	GNLXGenelux		Open for its score
	GRFSGrifois		Open for its score
	HROWHarrow		Open for its score
	IDXXIdexx Laboratories		Open for its score
19	GSKGSK	3/14	10

When does GSK report earnings, and what happens after?

Expected to report Wed Feb 3, before the open (in 86 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What GSK reported on Oct 28, 2026

The quarter

The figures are not read from the release yet.

The filing on EDGAR

Where the sales came from

GSK's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2031
Sales	more than £40 billion

Figures as filed (SEC filing, Oct 28)

4 more outlook lines, for Pro members.

In the company's words

“Accelerate Growth programme is targeting £1.9 billion of annual savings, to be fully realised by 2029, for expected total costs of £2.4 billion, of which £2.1 billion is expected to be cash costs.”

From its results filing (SEC filing · Oct 28)

The numbers

Market value: $101B; today
Sales: £33B; up 4.1% on the year
Profit: £5.7B; last fiscal year
Free cash flow: £6.4B; last fiscal year

Sales grew 6% a year over 5 years, fiscal 2020 to 2025.

Its figures are in GBP and its market value is in dollars, so no ratio of the two is worked out.

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on GSK: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-5.6%+3.3%-0.1%

Apr 29Jul 28Oct 28

Reported	When	Gap	Reaction	5 days
Oct 28, 2026No time given	No time given	-1.1%	-0.1%	+4.9%
Jul 28, 2026Before open	Before open	+4.3%	+3.3%	-0.9%
Apr 29, 2026Before open	Before open	-8.2%	-5.6%	-7.5%

GSK closed higher after 2 of its last 4 reports.

All 4 reports, and GSK's Quality Score going into each

GSK sales and profit by year

Sales and profit by year

Sales grew in six of the last seven years, to £33B in 2025. It made a profit in each of the eight years.

GSK has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on GSK, and all 14 on every stock.Get in free →

GSK RSI on Nov 6: 54.4, above its 50-day, below its 200-day

Not scored

RSI 54.4, MACD above signal, above its 50-day, below its 200-day. Not scored.13 readings

The deep dive on GSK

What it does and how it makes money2 findingsIt kept 24 cents of each dollar of sales in fiscal 2025: £7.93B of operating profit on £32.7B of sales.Annual report, filed Mar 6, 2026
Where it stands2 findingsFor Pro members2 findings on where GSK stands: its cash, debt, and share count, for Pro members
What changed in its filings3 findings"September 2025, GSK filed a patent and trademark infringement suit against Transpire in the United States District Court for the Southern District of Florida alleging Transpire’s proposed generic of Breo infringes GSK patents, trademarks, and trade dress." (20-F for fiscal 2025)SEC filing · Mar 6, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades GSK, for Pro members
Against its closest peers4 peersFor Pro membersGSK against 4 peers, fact by fact, for Pro members

7 more findings on GSK, each with its source, for Pro members.

GSK share count over time

Shares of GSK outstanding, as filed
Shares outstanding	As of
4.32B	Dec 31, 2025
4.31B	Dec 31, 2024
4.31B	Dec 31, 2023
4.31B	Dec 31, 2022

Offerings, shelves, and splits of GSK, from its filings
From its filings	Filed
Registered shares for a later sale (F-3ASR)	Mar 25, 2024

About GSK

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

66,841 employeesgsk.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on GSK and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move GSK's score: 4 things
18 more filings explained, a plain line each
Real-⁠time prices, no delay

See GSK's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: GSK's Quality Score is 10 (Average), #19 of 90 in Pharma.

What does GSK's Quality Score say?

GSK scores 10 today, which Breakaway calls Average. It is #19 of 90 in Pharma by Quality Score, with 3 of 14 chart checks firing. Down 1.2% on Oct 21 while the S&P 500 rose 0.5%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is GSK's Quality Score?

GSK scores 10 today, which Breakaway calls Average (6 to 10). That is #19 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GSK's 10.

When does GSK report earnings?

Expected to report Wed Feb 3, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. GSK closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.